ProShares Ultra NASDAQ Biotechnology
BIB
BIB
30 hedge funds and large institutions have $26M invested in ProShares Ultra NASDAQ Biotechnology in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
39% less capital invested
Capital invested by funds: $42.7M → $26M (-$16.7M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
30
Holding in Top 10
–
Calls
$22.2M
Puts
$11.8M
Top Buyers
| 1 | +$2.71M | |
| 2 | +$2.03M | |
| 3 | +$1.11M | |
| 4 |
ICAS
Investors Capital Advisory Services
Lynnfield,
Massachusetts
|
+$718K |
| 5 |
Jane Street
New York
|
+$512K |
Top Sellers
| 1 | -$2.73M | |
| 2 | -$1.04M | |
| 3 | -$763K | |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$397K |
| 5 |
BFC
Blue Fin Capital
Warren,
Rhode Island
|
-$370K |